|
Visual inspection: during the investigation, no significant deformations or damage of the valves was determined.Permeability test: a permeability test has shown that the valve is permeable.Computer controlled test: to test the valve, the opening pressure of the valve is measured using a computer-controlled miethke test device that simulates the flow of cerebrospinal fluid.The valve is tested in the horizontal position.The results show that the valve operates within the accepted tolerances in the horizontal position.Adjustment test: the progav 2.0 was tested and is not adjustable.Braking force and brake function test: the brake functionality test has shown that the brake function is operational, however the braking force cannot be measured due to the non-adjustability of the valve.Internal inspection: after dismantling of the valve, deposits were found inside.Result based on our test results, we can determine an accelerated outflow and a non-adjustability at the valve.The deposits visible in the valve have led to the functional impairments.Deposits caused by substances naturally present in the patient's body, such as protein, blood or tissue particles, are among the known and unavoidable risks and side effects of hydrocephalus therapy.Even small amounts of organic material can affect the integrity of the valve.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
|
|
It was reported that a progav 2.0 (#fx433t) was implanted during a procedure performed on (b)(6) 2023.According to the complainant, the valve showed adjustment difficulties.The patient underwent a revision procedure performed on (b)(6) 2024.The complainant device has returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: 6 years, 7 months.Weight: 17.4.Height: 111 cm.Gender: female.
|